October 18-20 | Tucson, AZ

The Research Institution GAP Fund and Accelerator Program Summit

UNC Rex’s venture fund expands by $8 million 

Get our GAP Insights Newsletter

Join Upcoming Events

October 18-20, 2023 / Tucson, AZ
The annual summit for research institution gap fund and accelerator programs, including proof of concept programs, startup accelerators, and university venture funds

The Story

UNC Rex Healthcare, which four years ago committed $10 million to create a venture capital fund that invests in startup health care companies, has set aside an extra $8 million for further investments.

The board of directors at Rex, which is part of the UNC Health Care System, has authorized the fund, Rex Health Ventures, to reinvest the $8 million that it has already reaped from its investments. That decision was made a few months ago but wasn’t publicized.

The new authorization, which comes on top of $2 million from the fund’s initial allocation that hasn’t yet been invested, leaves Rex Health Ventures with a total of $10 million to invest.

The additional money is both an endorsement of the fund’s financial performance to date and a testament to its ability to keep Rex in the loop on advances in health care, said Steve Burriss, president of Rex.

“It has exposed us to this whole world of innovation that exists,” he said.

Rex Health Ventures, one of just a few venture capital funds nationwide created and operated by a hospital, has invested about $8 million so far. Of the eight companies it has invested in, five are based in the Triangle: Aerial BioPharma, baebies, Midnight Pharma, Phononic and Target PharmaSolutions.

Venture capital investments are high-risk investments that can take years to pay off – if they pay off at all.

None of Rex Health Ventures’ portfolio companies have been acquired or have gone public – key events that trigger payouts to investors. But the fund has received $8 million in distributions to date from its portfolio companies – most notably from Aerial Biopharma, which sold the rights to an experimental drug for a $125 million upfront payment plus up to $272 million based on the achievement of undisclosed milestones.

Source: UNC Rex’s venture fund expands by $8 million | News & Observer

Get the Report

More GAP News